Evaluating prescription of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in patients with diabetes and albuminuria
CONCLUSION: ACEi/ARB therapy was suboptimal in patients with diabetes, hypertension, and albuminuria. Non-adherence was associated with CKD stage, possibly because of concerns about adverse events and healthcare-related factors.PMID:38606848 | DOI:10.5414/CN111247 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 12, 2024 Category: Urology & Nephrology Authors: Kittiphan Chienwichai Phirada Chaloemwa Sorawat Sangkaew Arunchai Chang Source Type: research
Effect of cyclophosphamide combined with glucocorticoid therapy on idiopathic membranous nephropathy: A multicenter open-label randomized controlled trial
CONCLUSION: Cyclophosphamide combined with glucocorticoid therapy is effective for improving the overall remission rate and can suppress inflammatory responses and oxidative stress in patients with idiopathic membranous nephropathy.PMID:38606849 | DOI:10.5414/CN111287 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 12, 2024 Category: Urology & Nephrology Authors: Jianlin Wang Dong Bian Jian Sun Source Type: research
Evaluating prescription of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in patients with diabetes and albuminuria
CONCLUSION: ACEi/ARB therapy was suboptimal in patients with diabetes, hypertension, and albuminuria. Non-adherence was associated with CKD stage, possibly because of concerns about adverse events and healthcare-related factors.PMID:38606848 | DOI:10.5414/CN111247 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 12, 2024 Category: Urology & Nephrology Authors: Kittiphan Chienwichai Phirada Chaloemwa Sorawat Sangkaew Arunchai Chang Source Type: research
Effect of cyclophosphamide combined with glucocorticoid therapy on idiopathic membranous nephropathy: A multicenter open-label randomized controlled trial
CONCLUSION: Cyclophosphamide combined with glucocorticoid therapy is effective for improving the overall remission rate and can suppress inflammatory responses and oxidative stress in patients with idiopathic membranous nephropathy.PMID:38606849 | DOI:10.5414/CN111287 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 12, 2024 Category: Urology & Nephrology Authors: Jianlin Wang Dong Bian Jian Sun Source Type: research
Evaluating prescription of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in patients with diabetes and albuminuria
CONCLUSION: ACEi/ARB therapy was suboptimal in patients with diabetes, hypertension, and albuminuria. Non-adherence was associated with CKD stage, possibly because of concerns about adverse events and healthcare-related factors.PMID:38606848 | DOI:10.5414/CN111247 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 12, 2024 Category: Urology & Nephrology Authors: Kittiphan Chienwichai Phirada Chaloemwa Sorawat Sangkaew Arunchai Chang Source Type: research
Effect of cyclophosphamide combined with glucocorticoid therapy on idiopathic membranous nephropathy: A multicenter open-label randomized controlled trial
CONCLUSION: Cyclophosphamide combined with glucocorticoid therapy is effective for improving the overall remission rate and can suppress inflammatory responses and oxidative stress in patients with idiopathic membranous nephropathy.PMID:38606849 | DOI:10.5414/CN111287 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 12, 2024 Category: Urology & Nephrology Authors: Jianlin Wang Dong Bian Jian Sun Source Type: research
Evaluating prescription of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in patients with diabetes and albuminuria
CONCLUSION: ACEi/ARB therapy was suboptimal in patients with diabetes, hypertension, and albuminuria. Non-adherence was associated with CKD stage, possibly because of concerns about adverse events and healthcare-related factors.PMID:38606848 | DOI:10.5414/CN111247 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 12, 2024 Category: Urology & Nephrology Authors: Kittiphan Chienwichai Phirada Chaloemwa Sorawat Sangkaew Arunchai Chang Source Type: research
Effect of cyclophosphamide combined with glucocorticoid therapy on idiopathic membranous nephropathy: A multicenter open-label randomized controlled trial
CONCLUSION: Cyclophosphamide combined with glucocorticoid therapy is effective for improving the overall remission rate and can suppress inflammatory responses and oxidative stress in patients with idiopathic membranous nephropathy.PMID:38606849 | DOI:10.5414/CN111287 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 12, 2024 Category: Urology & Nephrology Authors: Jianlin Wang Dong Bian Jian Sun Source Type: research
Tolvaptan therapy for edema in patients with chronic kidney disease
CONCLUSION: As long as a rational treatment regimen is followed, tolvaptan is a safe and effective diuretic for treating edema in CKD, even in the late stages of CKD without reducing residual renal function in the patients.PMID:38577748 | DOI:10.5414/CN111365 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 5, 2024 Category: Urology & Nephrology Authors: Li Zhou Qianqian Xu Xuehua Xi Xueying Yu Wenge Li Source Type: research
Tolvaptan therapy for edema in patients with chronic kidney disease
CONCLUSION: As long as a rational treatment regimen is followed, tolvaptan is a safe and effective diuretic for treating edema in CKD, even in the late stages of CKD without reducing residual renal function in the patients.PMID:38577748 | DOI:10.5414/CN111365 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 5, 2024 Category: Urology & Nephrology Authors: Li Zhou Qianqian Xu Xuehua Xi Xueying Yu Wenge Li Source Type: research
Tolvaptan therapy for edema in patients with chronic kidney disease
CONCLUSION: As long as a rational treatment regimen is followed, tolvaptan is a safe and effective diuretic for treating edema in CKD, even in the late stages of CKD without reducing residual renal function in the patients.PMID:38577748 | DOI:10.5414/CN111365 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 5, 2024 Category: Urology & Nephrology Authors: Li Zhou Qianqian Xu Xuehua Xi Xueying Yu Wenge Li Source Type: research
Tolvaptan therapy for edema in patients with chronic kidney disease
CONCLUSION: As long as a rational treatment regimen is followed, tolvaptan is a safe and effective diuretic for treating edema in CKD, even in the late stages of CKD without reducing residual renal function in the patients.PMID:38577748 | DOI:10.5414/CN111365 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 5, 2024 Category: Urology & Nephrology Authors: Li Zhou Qianqian Xu Xuehua Xi Xueying Yu Wenge Li Source Type: research
Tolvaptan therapy for edema in patients with chronic kidney disease
CONCLUSION: As long as a rational treatment regimen is followed, tolvaptan is a safe and effective diuretic for treating edema in CKD, even in the late stages of CKD without reducing residual renal function in the patients.PMID:38577748 | DOI:10.5414/CN111365 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 5, 2024 Category: Urology & Nephrology Authors: Li Zhou Qianqian Xu Xuehua Xi Xueying Yu Wenge Li Source Type: research
Tolvaptan therapy for edema in patients with chronic kidney disease
CONCLUSION: As long as a rational treatment regimen is followed, tolvaptan is a safe and effective diuretic for treating edema in CKD, even in the late stages of CKD without reducing residual renal function in the patients.PMID:38577748 | DOI:10.5414/CN111365 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 5, 2024 Category: Urology & Nephrology Authors: Li Zhou Qianqian Xu Xuehua Xi Xueying Yu Wenge Li Source Type: research
Acute kidney injury in children with lymphoma
CONCLUSION: TLS, lung infection, and lymphoma clinical stage were identified as independent risk factors for AKI in children with lymphoma during the first 30 days of hospitalization. Clinicians should increase their awareness of AKI in hospitalized patients with lymphoma.PMID:38529931 | DOI:10.5414/CN111157 (Source: Clinical Nephrology)
Source: Clinical Nephrology - March 26, 2024 Category: Urology & Nephrology Authors: Hejia Zhang Yanlong Duan Xiaoxue Li Zhi Chen Xiaorong Liu Source Type: research
